Late-stage biopharmaceutical company Aridis Pharmaceuticals, Inc. is pioneering the development of targeted immunotherapy using fully human monoclonal antibodies (mAb) for the treatment of life-threatening infections. The company's leading product candidate, AR-301, is a fully human mAb of immunoglobulin 1 (IgG1) that is currently in Phase III pivotal trials for the treatment of lung infections caused by S. aureus alphatoxin. In addition to AR-301, Aridis is developing other mAbs to target infections caused by a range of bacteria and viruses. These include AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin for the treatment of infections caused by methicillin-resistant and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb in Phase II trials targeting gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by P. aeruginosa serotype O11; AR-401, a preclinical stage treatment for infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy in Phase I/IIa clinical trial for the management of chronic lung infections in cystic fibrosis patients. Furthermore, Aridis is currently developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1 (IgG1) mAbs, which is in Phase I/II clinical trials for the treatment of mild to moderate non-hospitalized COVID-19 patients. Founded in 2003 and headquartered in Los Gatos, California, Aridis Pharmaceuticals is at the forefront of targeted immunotherapy development for the treatment of infectious diseases.